Technological advances will lead to improvements in clinical trials and greater participation in trials by patients, explained Michael Kolodziej, MD, national medical director of managed care strategy at Flatiron Health.
Technological advances will lead to improvements in clinical trials and greater participation in trials by patients, explained Michael Kolodziej, MD, national medical director of managed care strategy at Flatiron Health.
Transcript
How can improved technology improve patient access to clinical trials?
The consensus, I think, especially among community oncologists, is that the reason that so few patients get on clinical trials is that the system isn’t really set up for the community oncologist to succeed. The trials are too picky, they’re too labor-intensive, and, frankly, they cost money to perform. Technology can solve a lot of the problems that face successful participation in oncology trials. Everything from patient identification through identification of correct clinical characteristics that document that the patient is, in fact, eligible for the trial through—what I think historically and for old people like me, we remember the really thick binders—case report forms the ability to document the necessary details about the patient’s clinical course while on the trial, that really were administratively a tremendous burden.
So, I think technology could really facilitate successful execution and not only in the construct that we are accustomed to thinking about it, but if you take it a step further and if you start thinking about just-in-time clinical trials or clinical trials that are dependent on a rare biomarker—patient identification becomes much easier because there’s no longer a needle in the haystack phenomenon. We like to think that we understand how all of these drugs work and what the outcomes are going to be, but things happen and being able to query a system to look at alternative outcomes or a more comprehensive picture of the effects of the therapeutic intervention on the patient. I think it’s just a great opportunity. Nobody wants to stay where we are in clinical trials, it just doesn’t work.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More